Crossmark

Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy

Crossref DOI link: https://doi.org/10.1186/s12917-018-1424-1

Published Online: 2018-04-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

DeClue, Amy E. https://orcid.org/0000-0003-2177-397X
Axiak-Bechtel, Sandra M.

Zhang, Yan

Saha, Saurabh

Zhang, Linping

Tung, David D.

Bryan, Jeffrey N.
Funding

Funding for this research was provided by:

Biomed Valley Discoveries
License Information

Text and Data Mining valid from 2018-04-02
More Information

Article History

Received: 12 September 2017

Accepted: 13 March 2018

First Online: 2 April 2018

Ethics approval and consent to participate

: This study was approved by the University of Missouri Animal Care and Use Committee (protocol #7386). Written consent was obtained from the animal owners prior to enrollment.

: NA

: Some of the authors (SS, LZ, DT) are employed by the company which provided CNV-NT and the funding for this clinical trial.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.